Research Triangle Park, NC — Biopharmaceutical company Icagen today announced that, following a review of data
from recently completed clinical studies as well as the company’s proposed protocol for a phase 2 clinical trial in patients with
treatment resistant epilepsy, the FDA has notified the company that the clinical hold on Icagen’s IND for ICA-105665, a novel orally available
small molecule KCNQ potassium channel agonist, has been removed.
"We are pleased with the FDA’s action and will shortly be determining the next steps in the clinical development of our epilepsy drug candidate,
ICA-105665," noted President and CEO P. Kay Wagoner.
SOURCE: Icagen
